Esperion Therapeutics, Inc.
CEO
3 appearances
Latest appearance 2020-11-02
Tim Mayleben
CEO
Esperion Therapeutics, Inc.
Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.
About Tim Mayleben
Tim Mayleben is recorded as CEO at Esperion Therapeutics, Inc.. The proxy statement of Esperion Therapeutics, Inc. reports total compensation of $8,227,286 for Tim Mayleben in fiscal 2021, including a base salary of $265,152. Disclosed compensation is on record for 5 fiscal years. Tim Mayleben has spoken on 3 earnings calls across 1 company, most recently for Esperion Therapeutics, Inc. on November 2, 2020.
Summary generated from SEC filings and earnings-call records held by Equibles.
Affiliation history
Recorded current and former roles; source labels appear when available.
-
Esperion Therapeutics, Inc.
CEO
Proxy statement
Current
Company network
Recorded roles and call appearances connecting this person to public companies.
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2021 | Esperion Therapeutics, Inc. | Former Chief Executive Officer | $265,152 | $8,227,286 |
| 2020 | Esperion Therapeutics, Inc. | Former Chief Executive Officer | $700,000 | $6,925,024 |
| 2019 | Esperion Therapeutics, Inc. | Former Chief Executive Officer | $625,000 | $1,080,850 |
| 2018 | Esperion Therapeutics, Inc. | President and Chief Executive Officer | $600,000 | $9,724,839 |
| 2017 | Esperion Therapeutics, Inc. | President and Chief Executive Officer | $557,500 | $5,013,460 |
Recent activity
Earnings-call and investor-event appearances, plus filed executive appointments or departures, newest first.
-
Earnings call
Esperion Therapeutics, Inc. Q3 FY2020 Earnings Call
Esperion Therapeutics, Inc.
-
Earnings call
Esperion Therapeutics, Inc. Q2 FY2020 Earnings Call
Esperion Therapeutics, Inc.
-
Earnings call
Esperion Therapeutics, Inc. Q1 FY2020 Earnings Call
Esperion Therapeutics, Inc.